News

<p>The company&#0039;s proprietary insomnia agent, NG2-73, an alpha-3 preferring GABA partial agonist, achieved positive top-line results from two dose-ranging, phase 2b clinical trials.<br /><br />Multiple formulations were studied

The Alzheimer’s Society and drug makers Eisai and Pfizer want to overturn the watchdog’s decision not to approve a group of three drugs known as Aricept, Exelon and

The drug, TD-5108, is designed to treat chronic constipation and other disorders related to reduced gastrointestinal (GI) motility. Theravance says in the study, all three doses of TD-5108

The studies found that Prozac and Seroxat users developed thinner bones than those who did not take the selective serotonin reuptake inhibitors, or SSRIs. The drugs work by

The company intends to develop pharmaceutical products that use a botanical tobacco component for the treatment of smokeless tobacco dependence, as well as products that would utilize certain

The companies claim that by inhibiting a specific inflammatory process, T-5224 has the potential to block signs and symptoms of rheumatoid arthritis as well as the progressive destruction

Under the terms of the agreement, Yakult gains exclusive commercialization rights to satraplatin and will take the lead in developing the drug in Japan. Yakult will provide an

Being the first to file, Ranbaxy will enjoy 180-day exclusivity for pravastatin 80mg. According to the company, the annual sales for the heart drug are $209 million. Pravastatin

The European Commission approval of this expanded indication for Pegintron and Rebetol results in marketing authorization with unified labeling that is valid in the current EU 27 member